Revenue

3 Months Ended

Mar. 31, 2025

Principal Transaction Revenue [Line Items]

Revenue

Note 3. Revenue

Revenue consisted of the following:

	Three months ended March 31,
(In thousands of USD)	2025		2024
License revenue attributed from license performance obligation		—		—
License revenue attributed from R&D performance obligation		2,978		1,401
Total revenue		2,978		1,401

All revenue recognized from the R&D performance obligation was included within deferred revenue on the consolidated balance sheet as of the beginning of the applicable reporting period. There were no additions to deferred revenue during the reporting period.